Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients.

Standard

Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients. / Vischer, AS; Kuster, GM; Twerenbold, R; Pfister, O; Zhou, Q; Villiger, A; Poglitsch, M; Krähenbühl, S; Mayr, M; Osswald, S; Haschke, M; Burkard, T.

In: CELLS-BASEL, Vol. 10, No. 3, 534, 03.03.2021.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Vischer, AS, Kuster, GM, Twerenbold, R, Pfister, O, Zhou, Q, Villiger, A, Poglitsch, M, Krähenbühl, S, Mayr, M, Osswald, S, Haschke, M & Burkard, T 2021, 'Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients.', CELLS-BASEL, vol. 10, no. 3, 534. https://doi.org/10.3390/cells10030534

APA

Vischer, AS., Kuster, GM., Twerenbold, R., Pfister, O., Zhou, Q., Villiger, A., Poglitsch, M., Krähenbühl, S., Mayr, M., Osswald, S., Haschke, M., & Burkard, T. (2021). Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients. CELLS-BASEL, 10(3), [534]. https://doi.org/10.3390/cells10030534

Vancouver

Bibtex

@article{30defe6ca4624e58b918042819f796fe,
title = "Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients.",
abstract = "(1) Background: Recently, influences of antihypertensive treatment on the renin-angiotensin-aldosterone system (RAAS) has gained attention, regarding a possible influence on inflammatory and anti-inflammatory pathways. We aimed to study the effects of newly initiated antihypertensive drugs on angiotensin (Ang) II and Ang (1-7) as representers of two counter-regulatory axes. (2) Methods: In this randomized, open-label trial investigating RAAS peptides after the initiation of perindopril, olmesartan, amlodipine, or hydrochlorothiazide, Ang II and Ang (1-7) equilibrium concentrations were measured at 8 a.m. and 12 a.m. at baseline and after four weeks of treatment. Eighty patients were randomized (1:1:1:1 fashion). (3) Results: Between the four substances, we found significant differences regarding the concentrations of Ang II (p < 0.0005 for 8 a.m., 12 a.m.) and Ang (1-7) (p = 0.019 for 8 a.m., <0.0005 for 12 a.m.) four weeks after treatment start. Ang II was decreased by perindopril (p = 0.002), and increased by olmesartan (p < 0.0005), amlodipine (p = 0.012), and hydrochlorothiazide (p = 0.001). Ang (1-7) was increased by perindopril and olmesartan (p = 0.008/0.002), but not measurably altered by amlodipine and hydrochlorothiazide (p = 0.317/ 0.109). (4) Conclusion: The initiation of all first line antihypertensive treatments causes early and distinct alterations of equilibrium angiotensin levels. Given the additional AT1R blocking action of olmesartan, RAAS peptides shift upon initiation of perindopril and olmesartan appear to work in favor of the anti-inflammatory axis compared to amlodipine and hydrochlorothiazide.",
author = "AS Vischer and GM Kuster and R Twerenbold and O Pfister and Q Zhou and A Villiger and M Poglitsch and S Kr{\"a}henb{\"u}hl and M Mayr and S Osswald and M Haschke and T Burkard",
year = "2021",
month = mar,
day = "3",
doi = "10.3390/cells10030534",
language = "English",
volume = "10",
journal = "CELLS-BASEL",
issn = "2073-4409",
publisher = "MDPI Multidisciplinary Digital Publishing Institute",
number = "3",

}

RIS

TY - JOUR

T1 - Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients.

AU - Vischer, AS

AU - Kuster, GM

AU - Twerenbold, R

AU - Pfister, O

AU - Zhou, Q

AU - Villiger, A

AU - Poglitsch, M

AU - Krähenbühl, S

AU - Mayr, M

AU - Osswald, S

AU - Haschke, M

AU - Burkard, T

PY - 2021/3/3

Y1 - 2021/3/3

N2 - (1) Background: Recently, influences of antihypertensive treatment on the renin-angiotensin-aldosterone system (RAAS) has gained attention, regarding a possible influence on inflammatory and anti-inflammatory pathways. We aimed to study the effects of newly initiated antihypertensive drugs on angiotensin (Ang) II and Ang (1-7) as representers of two counter-regulatory axes. (2) Methods: In this randomized, open-label trial investigating RAAS peptides after the initiation of perindopril, olmesartan, amlodipine, or hydrochlorothiazide, Ang II and Ang (1-7) equilibrium concentrations were measured at 8 a.m. and 12 a.m. at baseline and after four weeks of treatment. Eighty patients were randomized (1:1:1:1 fashion). (3) Results: Between the four substances, we found significant differences regarding the concentrations of Ang II (p < 0.0005 for 8 a.m., 12 a.m.) and Ang (1-7) (p = 0.019 for 8 a.m., <0.0005 for 12 a.m.) four weeks after treatment start. Ang II was decreased by perindopril (p = 0.002), and increased by olmesartan (p < 0.0005), amlodipine (p = 0.012), and hydrochlorothiazide (p = 0.001). Ang (1-7) was increased by perindopril and olmesartan (p = 0.008/0.002), but not measurably altered by amlodipine and hydrochlorothiazide (p = 0.317/ 0.109). (4) Conclusion: The initiation of all first line antihypertensive treatments causes early and distinct alterations of equilibrium angiotensin levels. Given the additional AT1R blocking action of olmesartan, RAAS peptides shift upon initiation of perindopril and olmesartan appear to work in favor of the anti-inflammatory axis compared to amlodipine and hydrochlorothiazide.

AB - (1) Background: Recently, influences of antihypertensive treatment on the renin-angiotensin-aldosterone system (RAAS) has gained attention, regarding a possible influence on inflammatory and anti-inflammatory pathways. We aimed to study the effects of newly initiated antihypertensive drugs on angiotensin (Ang) II and Ang (1-7) as representers of two counter-regulatory axes. (2) Methods: In this randomized, open-label trial investigating RAAS peptides after the initiation of perindopril, olmesartan, amlodipine, or hydrochlorothiazide, Ang II and Ang (1-7) equilibrium concentrations were measured at 8 a.m. and 12 a.m. at baseline and after four weeks of treatment. Eighty patients were randomized (1:1:1:1 fashion). (3) Results: Between the four substances, we found significant differences regarding the concentrations of Ang II (p < 0.0005 for 8 a.m., 12 a.m.) and Ang (1-7) (p = 0.019 for 8 a.m., <0.0005 for 12 a.m.) four weeks after treatment start. Ang II was decreased by perindopril (p = 0.002), and increased by olmesartan (p < 0.0005), amlodipine (p = 0.012), and hydrochlorothiazide (p = 0.001). Ang (1-7) was increased by perindopril and olmesartan (p = 0.008/0.002), but not measurably altered by amlodipine and hydrochlorothiazide (p = 0.317/ 0.109). (4) Conclusion: The initiation of all first line antihypertensive treatments causes early and distinct alterations of equilibrium angiotensin levels. Given the additional AT1R blocking action of olmesartan, RAAS peptides shift upon initiation of perindopril and olmesartan appear to work in favor of the anti-inflammatory axis compared to amlodipine and hydrochlorothiazide.

UR - http://europepmc.org/abstract/med/33802464

U2 - 10.3390/cells10030534

DO - 10.3390/cells10030534

M3 - SCORING: Journal article

C2 - 33802464

VL - 10

JO - CELLS-BASEL

JF - CELLS-BASEL

SN - 2073-4409

IS - 3

M1 - 534

ER -